Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489346 | 0.92 | MRGPRX4 (0.46) | NR4A2NR4A1NR4A3MRGPRX4NPC1 | |
| SCHEMBL6489915 | 0.92 | NR4A2 (0.46) | NR4A2NR4A1NR4A3MRGPRX4NPC1 | |
| SCHEMBL6501198 | 0.91 | NR4A2 (0.48) | NR4A2NR4A1NR4A3MRGPRX4NPC1 | |
| SCHEMBL6489657 | 0.86 | KDM4C (0.42) | NR4A2NR4A1NR4A3MRGPRX4ALOX5AP | |
| SCHEMBL6489284 | 0.84 | PPARA (0.50) | MRGPRX4PPARG | |
| SCHEMBL7200058 | 0.84 | FABP3 (0.48) | MRGPRX4ALOX5AP | |
| SCHEMBL6498704 | 0.84 | P2RX3 (0.45) | MRGPRX4PPARG | |
| SCHEMBL6489503 | 0.84 | CYSLTR1 (0.42) | NR4A2MRGPRX4PPARGRXRA | |
| SCHEMBL6491685 | 0.83 | FABP3 (0.46) | MRGPRX4ALOX5AP | |
| SCHEMBL6490528 | 0.83 | DCTPP1 (0.42) | MRGPRX4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | NR4A2 2264/4885NR4A1 1583/4885NR4A3 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.